Leukemia Clinical Trials

Showing 6441-6460 of 10,987 trials

Complications After Endoscopic Retrograde Cholangiopancreatography

NCT04735224

Retrospective study to analyze benign complications and malignancy risks after ERCP with sphincterotomy. All patients who received a ERCP with sphincterotomy for a benign disease will be included. Post-ERCP hepato-biliary complications in the follow-up will be registered.

Choledocholithiasis With Acute Cholangitis (Diagnosis)Acute Pancreatitis Due to Gallstones

Juan Carlos Martín del Olmo500 participantsStarted Jan 2017

COMPLETEDPhase 2

Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)

NCT01207440

The purpose of this study is to determine the efficacy of ponatinib in patients with chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast phase (BP) or with philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who either are resistant or intolerant to either dasatinib or nilotinib, or have the (T)hreonine-315-(I)soleucine (T315I) mutation.

Chronic Myeloid LeukemiaPh+ Acute Lymphoblastic Leukemia

Ariad Pharmaceuticals449 participantsStarted Sep 2010

St Leonards, New South Wales, Australia • Woolloongabba, Queensland, Australia • Adelaide, South Australia, Australia +39 more locations

Complications After Endoscopic Retrograde Cholangiopancreatography

Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)

Related Searches

BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases

HYPOPhosphatemia in the Intensive Care: A One-day Point Prevalence Survey

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression

CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)

Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma

Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 Insertions

COVID-19 Vaccine in Patients After Allogeneic HCT, CAR-T Therapy and With Primary Immune Deficiency

The Efficacy of Preseasonal Omalizumab Treatment

A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)

Withdrawal of Immunosuppression in Recipients of Face and Extremity Transplants

Study in Patients With SCLC of Veliparib in Combination With Topotecan

Combined Haploidentical-Cord Blood Transplantation for Adults and Children

Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers

A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001)

Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial

The Transformation of Locally Advanced Pancreatic Cancer.

Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung